Navigation Links
Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
Date:3/31/2008

LONG BEACH, N.Y., March 31 /PRNewswire-FirstCall/ -- Chem Rx Corporation (OTC Bulletin Board: PMQC; PMQCU; PMQCW), a leading provider of institutional pharmacy services, announced today that it will hold a conference call to review 2007 financial results and discuss 2008 outlook on April 1, 2008 at 8:30 a.m. EDT. Jerry Silva, Chairman and Chief Executive Officer and Steven C. Silva, President and Chief Operating Officer, will host the conference call. A press release announcing 2007 year-end results and 2008 guidance will be issued this evening.

To participate in the conference call, please dial 1-877-407-0784 (USA) or 1-201-689-8560 (international). In addition, a dial-up replay of the conference call will be available beginning April 1, 2008 at approximately 10:30 a.m. ET and will remain available until April 8, 2008. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 280675. A web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.chemrx.net through April 29, 2008.

About Chem Rx Corporation

Founded more than 40 years ago, Chem Rx Corporation is a leading provider of institutional pharmacy services in the New York City metropolitan area, as well as parts of New Jersey, upstate New York, and Pennsylvania. Chem Rx's client base includes skilled nursing facilities and a wide range of other long-term care facilities. Through its services, Chem Rx provides more than 65,000 institutional residents with prescription and non-prescription drugs, intravenous medications, durable medical equipment items and surgical supplies. Chem Rx's website address is http://www.chemrx.net.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of Chem Rx's management and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: compliance with government regulations; changes in legislation or regulatory environments; requirements or changes adversely affecting the health care industry, including changes in Medicare reimbursement policies; fluctuations in customer demand; management of rapid growth; intensity of competition; timing, approval and market acceptance of new product introductions and institutional pharmacy locations; general economic conditions; geopolitical events and regulatory changes, as well as other relevant risks detailed in Chem Rx's filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. Chem Rx Corporation does not assume any obligation to update the information contained in this press release.

Contacts: The Ruth Group

Steven C. Silva Investor Relations

President and Chief Operating Stephanie Carrington / Jared Hoffman

Officer (646) 536-7017 / 7013

Chem Rx Corporation scarrington@theruthgroup.com

516-889-8770 jhoffman@theruthgroup.com


'/>"/>
SOURCE Chem Rx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Immunosyn Corporation Announces 2007 Results, Files 10KSB
2. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
3. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
4. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
5. Psychemedics Corporation Authorizes A 250,000 Share Stock Repurchase Program
6. Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics
7. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results
8. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
9. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
10. Somanetics Corporation to Present at Cowen & Company 28th Annual Health Care Conference
11. MannKind Corporation Response to Recent Market Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 21, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 American Society ... San Francisco . In ... administered investigational agent designed to inhibit cancer stemness pathways ...
(Date:1/20/2017)... , January 20, 2017 ... market conditions have influenced the most recent performances of ... Inc. (NASDAQ: RGLS ), Abeona Therapeutics Inc. ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... report by Grand View Research, global Biotech market size is expected ...
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... -- Research and Markets has announced the addition of ... Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" report ... ... projected to reach $15,737 million by 2022 from $6,521 in 2015, ... Omic technologies segment accounted for more than half of ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017  Michael Johnson, co-founder of Visikol Inc. a company ... has been named to the elite "Forbes 30 Under 30" list ... 600 people in 20 fields nationwide to be recognized as a ... applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
Breaking Biology News(10 mins):